市場調査レポート

商品コード

1476380

急性群発発作の2030年までの市場予測：製品タイプ、投与経路、流通チャネル、エンドユーザー、地域別の世界分析

Acute Repetitive Seizures Market Forecasts to 2030 - Global Analysis By Product (Diastat Rectal Gel, AZ-002, NRL-1, USL-261 and Other Products), Drug Type, Route of Administration, Distribution Channel, End User and By Geography

出版日: 2024年05月05日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,150 595,815円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 753,742円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 911,669円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,076,775円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、世界の急性群発発作市場は2023年に29億米ドルを占め、予測期間中のCAGRは14.4％で成長し、2030年には76億米ドルに達すると予測されています。

急性群発発作（Acute Repetitive Seizures：ARS）とは、比較的短期間、典型的には24時間以内に連続して起こるてんかん発作のことです。これらの発作は反復性であることが特徴で、服薬順守などの通常の発作抑制策にもかかわらず起こることがあります。これらの発作は様々なタイプのてんかんに起こる可能性があり、速やかに発作を制御しなければ生命を脅かす危険性があるため、発作を管理し、さらなる発作を防ぐために緊急の医療措置が必要となる場合があります。

世界保健機関（WHO）によると、てんかんは世界中で約5,000万人が罹患している神経疾患です。

てんかん有病率の上昇

同市場では、てんかん有病率の増加が懸念されています。この動向は、繰り返し起こる予測不可能な発作に罹患する人口の増加を示しており、高度な治療介入や管理戦略が必要とされています。てんかん患者の急増は、この神経疾患と闘う人々が直面する複雑な課題に対処するため、革新的な治療、個別化されたケアプラン、啓発キャンペーンの強化が急務であることを裏付けています。

認識不足

てんかん治療が大きく進歩しているにもかかわらず、市場における認知度の低さは依然として顕著です。ヘルスケアプロバイダーや一般の人々を含む多くの人々は、患者が直面する課題や利用可能な治療選択肢を十分に理解していない可能性があります。このような認識のギャップは、タイムリーな診断、適切な管理、革新的な治療法へのアクセスの妨げとなっており、管理の成果を改善するための的を絞った教育やアドボカシー活動の必要性を浮き彫りにしています。

新薬の開発

発作の発生に関与する特定のイオンチャネルや神経伝達系を標的とするなど、新たな作用機序の研究が進められています。さらに、経鼻製剤や経皮製剤のようなドラッグデリバリー方法の進歩は、患者のコンプライアンスと治療成績の向上を目指しています。このような努力は、てんかん患者に対する治療選択肢を最適化するための積極的なアプローチを意味します。

高い治療費

急性反復性発作（ARS）市場における治療費の高さは重大な懸念事項であり、しばしば患者やヘルスケアシステムの経済的能力を超えています。治療費には診断検査、投薬、入院、継続的なモニタリングなどが含まれ、経済的負担が大きいです。この費用の壁は、必要不可欠な治療法へのアクセスを制限し、患者の転帰と生活の質に影響を与える可能性があります。

COVID-19の影響：

COVID-19の大流行は、急性反復性発作（ARS）市場に大きな影響を与えました。ヘルスケアサービスへのアクセスが途絶え、多くの患者の診断と治療の遅れにつながった。臨床試験や研究イニシアティブも後退に直面し、新しい治療法の開発に影響を与えました。しかし、遠隔医療や遠隔モニタリングが普及し、患者管理の代替手段が提供されるようになった。

予測期間中、バルビツール酸薬セグメントが最大となる見込み

バルビツール酸薬セグメントは予測期間中最大となる見込みです。バルビツール酸系薬剤は長年の選択肢であったが、安全性への懸念やより効果的な新薬の開発により、その使用は減少しています。市場では、バルビツール酸系薬剤は、他の治療法が無効であったり禁忌であったりする特定の症例に対するニッチな役割を担っています。フェノバルビタールのようなバルビツール酸系薬剤は、その使用は限定的であるにもかかわらず、特に資源が限られた環境や個々の患者のニーズに合わせた場合に、特定の患者にとって実行可能な選択肢であり続けています。

予測期間中にCAGRが最も高くなると予想されるのは、在宅ケア分野です。

予測期間中にCAGRが最も高くなると予想されるのは、在宅ケア環境分野です。在宅介護環境には、モニタリング機器、介護者トレーニング、緊急対応計画など、さまざまなサービスが含まれます。遠隔医療や遠隔モニタリング技術の進歩に伴い、在宅ケア環境はますます高度化し、急性群発発作を管理する個人の利便性と快適性を向上させながら、リアルタイムの介入を可能にし、患者の転帰を改善しています。

最大のシェアを占める地域：

北米は、認知度の向上、診断技術の改善、患者数の増加などの要因により、予測期間中最大の市場シェアを占めると予測されます。この市場の主なプレーヤーは、アンメット・メディカル・ニーズに対応するための先進的な治療法や薬剤の開発に注力しています。さらに、政府の取り組みやヘルスケア改革は、ARS治療へのアクセス強化に重要な役割を果たしており、同地域における市場拡大の有望な見通しにつながっています。

CAGRが最も高い地域：

予測期間中、アジア太平洋地域のCAGRが最も高いと予測されます。ARSは深刻な疾患であり、同地域では相当数の人々が罹患しています。啓発キャンペーンや診断の改善により、この疾患に対する理解が深まり、効果的な治療法に対する需要が高まっています。製薬会社、研究機関、ヘルスケアプロバイダー間の競合が、ARS治療の革新と低価格化を促進しています。

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

企業プロファイル
- 追加市場プレーヤーの包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域セグメンテーション
- 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他欧州
アジア太平洋地域
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他アジア太平洋地域
南米
- アルゼンチン
- ブラジル
- チリ
- その他南米
中東・アフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他中東とアフリカ

第11章主な発展

契約、パートナーシップ、コラボレーション、合弁事業
買収と合併
新製品発売
事業拡大
その他の主要戦略

第12章企業プロファイリング

Bausch Health Companies Inc.
UCB Pharma
Eisai Co., Ltd.
SK Biopharmaceuticals Co., Ltd.
Valeant Pharmaceuticals North America LLC
Sunovion Pharmaceuticals
GW Pharmaceuticals
Pfizer Inc.
Marinus Pharmaceuticals
Neurelis, Inc.
Sanofi
Novartis AG
Alexza
Veriton Pharma

図表

List of Tables

Table 1 Global Acute Repetitive Seizures Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Acute Repetitive Seizures Market Outlook, By Product (2021-2030) ($MN)
Table 3 Global Acute Repetitive Seizures Market Outlook, By Diastat Rectal Gel (2021-2030) ($MN)
Table 4 Global Acute Repetitive Seizures Market Outlook, By AZ-002 (2021-2030) ($MN)
Table 5 Global Acute Repetitive Seizures Market Outlook, By NRL-1 (2021-2030) ($MN)
Table 6 Global Acute Repetitive Seizures Market Outlook, By USL-261 (2021-2030) ($MN)
Table 7 Global Acute Repetitive Seizures Market Outlook, By Other Products (2021-2030) ($MN)
Table 8 Global Acute Repetitive Seizures Market Outlook, By Drug Type (2021-2030) ($MN)
Table 9 Global Acute Repetitive Seizures Market Outlook, By Benzodiazepines (2021-2030) ($MN)
Table 10 Global Acute Repetitive Seizures Market Outlook, By Barbiturates (2021-2030) ($MN)
Table 11 Global Acute Repetitive Seizures Market Outlook, By Antiepileptic Drugs (AEDs) (2021-2030) ($MN)
Table 12 Global Acute Repetitive Seizures Market Outlook, By Other Drug Types (2021-2030) ($MN)
Table 13 Global Acute Repetitive Seizures Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 14 Global Acute Repetitive Seizures Market Outlook, By Intranasal Formulations (2021-2030) ($MN)
Table 15 Global Acute Repetitive Seizures Market Outlook, By Oral (2021-2030) ($MN)
Table 16 Global Acute Repetitive Seizures Market Outlook, By Intravenous (2021-2030) ($MN)
Table 17 Global Acute Repetitive Seizures Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 18 Global Acute Repetitive Seizures Market Outlook, By Specialty Clinics (2021-2030) ($MN)
Table 19 Global Acute Repetitive Seizures Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 20 Global Acute Repetitive Seizures Market Outlook, By Hospitals (2021-2030) ($MN)
Table 21 Global Acute Repetitive Seizures Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 22 Global Acute Repetitive Seizures Market Outlook, By End User (2021-2030) ($MN)
Table 23 Global Acute Repetitive Seizures Market Outlook, By Home Care Settings (2021-2030) ($MN)
Table 24 Global Acute Repetitive Seizures Market Outlook, By Clinics (2021-2030) ($MN)
Table 25 Global Acute Repetitive Seizures Market Outlook, By Other End Users (2021-2030) ($MN)
Table 26 North America Acute Repetitive Seizures Market Outlook, By Country (2021-2030) ($MN)
Table 27 North America Acute Repetitive Seizures Market Outlook, By Product (2021-2030) ($MN)
Table 28 North America Acute Repetitive Seizures Market Outlook, By Diastat Rectal Gel (2021-2030) ($MN)
Table 29 North America Acute Repetitive Seizures Market Outlook, By AZ-002 (2021-2030) ($MN)
Table 30 North America Acute Repetitive Seizures Market Outlook, By NRL-1 (2021-2030) ($MN)
Table 31 North America Acute Repetitive Seizures Market Outlook, By USL-261 (2021-2030) ($MN)
Table 32 North America Acute Repetitive Seizures Market Outlook, By Other Products (2021-2030) ($MN)
Table 33 North America Acute Repetitive Seizures Market Outlook, By Drug Type (2021-2030) ($MN)
Table 34 North America Acute Repetitive Seizures Market Outlook, By Benzodiazepines (2021-2030) ($MN)
Table 35 North America Acute Repetitive Seizures Market Outlook, By Barbiturates (2021-2030) ($MN)
Table 36 North America Acute Repetitive Seizures Market Outlook, By Antiepileptic Drugs (AEDs) (2021-2030) ($MN)
Table 37 North America Acute Repetitive Seizures Market Outlook, By Other Drug Types (2021-2030) ($MN)
Table 38 North America Acute Repetitive Seizures Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 39 North America Acute Repetitive Seizures Market Outlook, By Intranasal Formulations (2021-2030) ($MN)
Table 40 North America Acute Repetitive Seizures Market Outlook, By Oral (2021-2030) ($MN)
Table 41 North America Acute Repetitive Seizures Market Outlook, By Intravenous (2021-2030) ($MN)
Table 42 North America Acute Repetitive Seizures Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 43 North America Acute Repetitive Seizures Market Outlook, By Specialty Clinics (2021-2030) ($MN)
Table 44 North America Acute Repetitive Seizures Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 45 North America Acute Repetitive Seizures Market Outlook, By Hospitals (2021-2030) ($MN)
Table 46 North America Acute Repetitive Seizures Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 47 North America Acute Repetitive Seizures Market Outlook, By End User (2021-2030) ($MN)
Table 48 North America Acute Repetitive Seizures Market Outlook, By Home Care Settings (2021-2030) ($MN)
Table 49 North America Acute Repetitive Seizures Market Outlook, By Clinics (2021-2030) ($MN)
Table 50 North America Acute Repetitive Seizures Market Outlook, By Other End Users (2021-2030) ($MN)
Table 51 Europe Acute Repetitive Seizures Market Outlook, By Country (2021-2030) ($MN)
Table 52 Europe Acute Repetitive Seizures Market Outlook, By Product (2021-2030) ($MN)
Table 53 Europe Acute Repetitive Seizures Market Outlook, By Diastat Rectal Gel (2021-2030) ($MN)
Table 54 Europe Acute Repetitive Seizures Market Outlook, By AZ-002 (2021-2030) ($MN)
Table 55 Europe Acute Repetitive Seizures Market Outlook, By NRL-1 (2021-2030) ($MN)
Table 56 Europe Acute Repetitive Seizures Market Outlook, By USL-261 (2021-2030) ($MN)
Table 57 Europe Acute Repetitive Seizures Market Outlook, By Other Products (2021-2030) ($MN)
Table 58 Europe Acute Repetitive Seizures Market Outlook, By Drug Type (2021-2030) ($MN)
Table 59 Europe Acute Repetitive Seizures Market Outlook, By Benzodiazepines (2021-2030) ($MN)
Table 60 Europe Acute Repetitive Seizures Market Outlook, By Barbiturates (2021-2030) ($MN)
Table 61 Europe Acute Repetitive Seizures Market Outlook, By Antiepileptic Drugs (AEDs) (2021-2030) ($MN)
Table 62 Europe Acute Repetitive Seizures Market Outlook, By Other Drug Types (2021-2030) ($MN)
Table 63 Europe Acute Repetitive Seizures Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 64 Europe Acute Repetitive Seizures Market Outlook, By Intranasal Formulations (2021-2030) ($MN)
Table 65 Europe Acute Repetitive Seizures Market Outlook, By Oral (2021-2030) ($MN)
Table 66 Europe Acute Repetitive Seizures Market Outlook, By Intravenous (2021-2030) ($MN)
Table 67 Europe Acute Repetitive Seizures Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 68 Europe Acute Repetitive Seizures Market Outlook, By Specialty Clinics (2021-2030) ($MN)
Table 69 Europe Acute Repetitive Seizures Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 70 Europe Acute Repetitive Seizures Market Outlook, By Hospitals (2021-2030) ($MN)
Table 71 Europe Acute Repetitive Seizures Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 72 Europe Acute Repetitive Seizures Market Outlook, By End User (2021-2030) ($MN)
Table 73 Europe Acute Repetitive Seizures Market Outlook, By Home Care Settings (2021-2030) ($MN)
Table 74 Europe Acute Repetitive Seizures Market Outlook, By Clinics (2021-2030) ($MN)
Table 75 Europe Acute Repetitive Seizures Market Outlook, By Other End Users (2021-2030) ($MN)
Table 76 Asia Pacific Acute Repetitive Seizures Market Outlook, By Country (2021-2030) ($MN)
Table 77 Asia Pacific Acute Repetitive Seizures Market Outlook, By Product (2021-2030) ($MN)
Table 78 Asia Pacific Acute Repetitive Seizures Market Outlook, By Diastat Rectal Gel (2021-2030) ($MN)
Table 79 Asia Pacific Acute Repetitive Seizures Market Outlook, By AZ-002 (2021-2030) ($MN)
Table 80 Asia Pacific Acute Repetitive Seizures Market Outlook, By NRL-1 (2021-2030) ($MN)
Table 81 Asia Pacific Acute Repetitive Seizures Market Outlook, By USL-261 (2021-2030) ($MN)
Table 82 Asia Pacific Acute Repetitive Seizures Market Outlook, By Other Products (2021-2030) ($MN)
Table 83 Asia Pacific Acute Repetitive Seizures Market Outlook, By Drug Type (2021-2030) ($MN)
Table 84 Asia Pacific Acute Repetitive Seizures Market Outlook, By Benzodiazepines (2021-2030) ($MN)
Table 85 Asia Pacific Acute Repetitive Seizures Market Outlook, By Barbiturates (2021-2030) ($MN)
Table 86 Asia Pacific Acute Repetitive Seizures Market Outlook, By Antiepileptic Drugs (AEDs) (2021-2030) ($MN)
Table 87 Asia Pacific Acute Repetitive Seizures Market Outlook, By Other Drug Types (2021-2030) ($MN)
Table 88 Asia Pacific Acute Repetitive Seizures Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 89 Asia Pacific Acute Repetitive Seizures Market Outlook, By Intranasal Formulations (2021-2030) ($MN)
Table 90 Asia Pacific Acute Repetitive Seizures Market Outlook, By Oral (2021-2030) ($MN)
Table 91 Asia Pacific Acute Repetitive Seizures Market Outlook, By Intravenous (2021-2030) ($MN)
Table 92 Asia Pacific Acute Repetitive Seizures Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 93 Asia Pacific Acute Repetitive Seizures Market Outlook, By Specialty Clinics (2021-2030) ($MN)
Table 94 Asia Pacific Acute Repetitive Seizures Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 95 Asia Pacific Acute Repetitive Seizures Market Outlook, By Hospitals (2021-2030) ($MN)
Table 96 Asia Pacific Acute Repetitive Seizures Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 97 Asia Pacific Acute Repetitive Seizures Market Outlook, By End User (2021-2030) ($MN)
Table 98 Asia Pacific Acute Repetitive Seizures Market Outlook, By Home Care Settings (2021-2030) ($MN)
Table 99 Asia Pacific Acute Repetitive Seizures Market Outlook, By Clinics (2021-2030) ($MN)
Table 100 Asia Pacific Acute Repetitive Seizures Market Outlook, By Other End Users (2021-2030) ($MN)
Table 101 South America Acute Repetitive Seizures Market Outlook, By Country (2021-2030) ($MN)
Table 102 South America Acute Repetitive Seizures Market Outlook, By Product (2021-2030) ($MN)
Table 103 South America Acute Repetitive Seizures Market Outlook, By Diastat Rectal Gel (2021-2030) ($MN)
Table 104 South America Acute Repetitive Seizures Market Outlook, By AZ-002 (2021-2030) ($MN)
Table 105 South America Acute Repetitive Seizures Market Outlook, By NRL-1 (2021-2030) ($MN)
Table 106 South America Acute Repetitive Seizures Market Outlook, By USL-261 (2021-2030) ($MN)
Table 107 South America Acute Repetitive Seizures Market Outlook, By Other Products (2021-2030) ($MN)
Table 108 South America Acute Repetitive Seizures Market Outlook, By Drug Type (2021-2030) ($MN)
Table 109 South America Acute Repetitive Seizures Market Outlook, By Benzodiazepines (2021-2030) ($MN)
Table 110 South America Acute Repetitive Seizures Market Outlook, By Barbiturates (2021-2030) ($MN)
Table 111 South America Acute Repetitive Seizures Market Outlook, By Antiepileptic Drugs (AEDs) (2021-2030) ($MN)
Table 112 South America Acute Repetitive Seizures Market Outlook, By Other Drug Types (2021-2030) ($MN)
Table 113 South America Acute Repetitive Seizures Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 114 South America Acute Repetitive Seizures Market Outlook, By Intranasal Formulations (2021-2030) ($MN)
Table 115 South America Acute Repetitive Seizures Market Outlook, By Oral (2021-2030) ($MN)
Table 116 South America Acute Repetitive Seizures Market Outlook, By Intravenous (2021-2030) ($MN)
Table 117 South America Acute Repetitive Seizures Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 118 South America Acute Repetitive Seizures Market Outlook, By Specialty Clinics (2021-2030) ($MN)
Table 119 South America Acute Repetitive Seizures Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 120 South America Acute Repetitive Seizures Market Outlook, By Hospitals (2021-2030) ($MN)
Table 121 South America Acute Repetitive Seizures Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 122 South America Acute Repetitive Seizures Market Outlook, By End User (2021-2030) ($MN)
Table 123 South America Acute Repetitive Seizures Market Outlook, By Home Care Settings (2021-2030) ($MN)
Table 124 South America Acute Repetitive Seizures Market Outlook, By Clinics (2021-2030) ($MN)
Table 125 South America Acute Repetitive Seizures Market Outlook, By Other End Users (2021-2030) ($MN)
Table 126 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Country (2021-2030) ($MN)
Table 127 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Product (2021-2030) ($MN)
Table 128 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Diastat Rectal Gel (2021-2030) ($MN)
Table 129 Middle East & Africa Acute Repetitive Seizures Market Outlook, By AZ-002 (2021-2030) ($MN)
Table 130 Middle East & Africa Acute Repetitive Seizures Market Outlook, By NRL-1 (2021-2030) ($MN)
Table 131 Middle East & Africa Acute Repetitive Seizures Market Outlook, By USL-261 (2021-2030) ($MN)
Table 132 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Other Products (2021-2030) ($MN)
Table 133 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Drug Type (2021-2030) ($MN)
Table 134 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Benzodiazepines (2021-2030) ($MN)
Table 135 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Barbiturates (2021-2030) ($MN)
Table 136 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Antiepileptic Drugs (AEDs) (2021-2030) ($MN)
Table 137 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Other Drug Types (2021-2030) ($MN)
Table 138 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 139 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Intranasal Formulations (2021-2030) ($MN)
Table 140 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Oral (2021-2030) ($MN)
Table 141 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Intravenous (2021-2030) ($MN)
Table 142 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 143 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Specialty Clinics (2021-2030) ($MN)
Table 144 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 145 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Hospitals (2021-2030) ($MN)
Table 146 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 147 Middle East & Africa Acute Repetitive Seizures Market Outlook, By End User (2021-2030) ($MN)
Table 148 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Home Care Settings (2021-2030) ($MN)
Table 149 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Clinics (2021-2030) ($MN)
Table 150 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Other End Users (2021-2030) ($MN)

Product Code: SMRC25926

According to Stratistics MRC, the Global Acute Repetitive Seizures Market is accounted for $2.9 billion in 2023 and is expected to reach $7.6 billion by 2030 growing at a CAGR of 14.4% during the forecast period. Acute Repetitive Seizures (ARS) is a series of epileptic seizures that occur in rapid succession within a relatively short period, typically within 24 hours. These seizures are characterized by their repetitive nature and can occur despite the person's normal seizure control measures, such as medication adherence. They can occur in various types of epilepsy and may require urgent medical attention to manage and prevent further seizures, as they can be dangerous and potentially life-threatening if not controlled promptly.

According to World Health Organization (WHO), epilepsy is a neurological condition affecting about 50 million people worldwide.

Market Dynamics:

Driver:

Rising prevalence of epilepsy

The market is witnessing a concerning rise in epilepsy prevalence. This trend indicates a growing population affected by recurrent and unpredictable seizures, necessitating advanced therapeutic interventions and management strategies. The surge in epilepsy cases within the sector underscores the pressing need for innovative treatments, personalized care plans, and heightened awareness campaigns to address the complex challenges faced by individuals grappling with this neurological disorder.

Restraint:

Lack of awareness

Despite significant advancements in epilepsy treatment, there remains a notable lack of awareness in the market. Many individuals, including healthcare providers and the general public, may not fully grasp the challenges faced by patients or the available therapeutic options. This gap in awareness hinders timely diagnosis, appropriate management, and access to innovative treatments, highlighting the need for targeted education and advocacy efforts to improve outcomes in management.

Opportunity:

Development of new drugs

Research is geared towards novel mechanisms of action, such as targeting specific ion channels or neurotransmitter systems implicated in seizure generation. Additionally, advancements in drug delivery methods, like intranasal or transdermal formulations, aim to improve patient compliance and treatment outcomes. These efforts signify a proactive approach to optimizing therapeutic options for individuals with the market.

Threat:

High cost of treatment

The high cost of treatment in the Acute Repetitive Seizures (ARS) market is a significant concern, often exceeding the financial capacities of patients and healthcare systems alike. The expenses encompass diagnostic tests, medications, hospitalizations, and ongoing monitoring, creating a considerable financial burden. This cost barrier can limit access to essential therapies, impacting patient outcomes and quality of life.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the Acute Repetitive Seizures (ARS) market. Access to healthcare services was disrupted, leading to delayed diagnosis and treatment for many patients. Clinical trials and research initiatives also faced setbacks, affecting the development of new therapies. However, telemedicine and remote monitoring gained traction, offering alternative ways to manage patients.

The barbiturates segment is expected to be the largest during the forecast period

The barbiturates segment is expected to be the largest during the forecast period. Barbiturates have been a longstanding option, but their use has declined due to safety concerns and the development of newer, more effective medications. In the market, they occupy a niche role for specific cases where other treatments have failed or are contraindicated. Despite their limited use, barbiturates like phenobarbital remain a viable option for certain patients, particularly in resource-limited settings or when tailored to individual patient needs.

The home care settings segment is expected to have the highest CAGR during the forecast period

The home care settings segment is expected to have the highest CAGR during the forecast period. These settings encompass a range of services, including monitoring equipment, caregiver training, and emergency response plans. With advancements in telemedicine and remote monitoring technologies, home care settings have become increasingly sophisticated, enabling real-time interventions and improving patient outcomes while enhancing convenience and comfort for individuals managing acute repetitive seizures.

Region with largest share:

North America is projected to hold the largest market share during the forecast period driven by factors such as increasing awareness, improved diagnostic technologies, and a growing patient population. Key players in this market focus on developing advanced therapies and medications to address unmet medical needs. Additionally, government initiatives and healthcare reforms are playing a crucial role in enhancing access to ARS treatments, leading to a promising outlook for market expansion in the region.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. It is a serious condition that affects a significant number of people in the region. Awareness campaigns and improved diagnosis have contributed to a better understanding of the condition, leading to increased demand for effective treatments. Competition among pharmaceutical companies, research institutions, and healthcare providers drives innovation and affordability in ARS treatments.

Key players in the market

Some of the key players in Acute Repetitive Seizures market include Bausch Health Companies Inc., UCB Pharma, Eisai Co., Ltd., SK Biopharmaceuticals Co., Ltd., Valeant Pharmaceuticals North America LLC, Sunovion Pharmaceuticals, GW Pharmaceuticals, Pfizer Inc., Marinus Pharmaceuticals, Neurelis, Inc., Sanofi, Novartis AG, Alexza and Veriton Pharma.

Key Developments:

In May 2019, UCB declared that the U.S. FDA has permitted a New Drug Application for the company's latest anti-epileptic drug (AED) NAYZILAM(R) nasal spray CIV. It is a benzodiazepine designated for the stereotypic incidents of recurrent seizure activity and acute treatment of intermittent that are different from a patient's normal seizure form in person with epilepsy 12 years and older1.

In September 2018, Neurelis, Inc., a pharmaceutical firm based in San Diego, California, submitted a New Drug Application (NDA) to the FDA for VALTOCO as a treatment for epilepsy patients with acute repeated seizures.

Products Covered:

Diastat Rectal Gel
AZ-002
NRL-1
USL-261
Other Products

Drug Types Covered:

Benzodiazepines
Barbiturates
Antiepileptic Drugs (AEDs)
Other Drug Types

Route of Administrations Covered:

Intranasal Formulations
Oral
Intravenous

Distribution Channels Covered:

Specialty Clinics
Retail Pharmacies
Hospitals
Online Pharmacies

End Users Covered:

Home Care Settings
Clinics
Other End Users

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Acute Repetitive Seizures Market, By Product

5.1 Introduction
5.2 Diastat Rectal Gel
5.3 AZ-002
5.4 NRL-1
5.5 USL-261
5.6 Other Products

6 Global Acute Repetitive Seizures Market, By Drug Type

6.1 Introduction
6.2 Benzodiazepines
6.3 Barbiturates
6.4 Antiepileptic Drugs (AEDs)
6.5 Other Drug Types

7 Global Acute Repetitive Seizures Market, By Route of Administration

7.1 Introduction
7.2 Intranasal Formulations
7.3 Oral
7.4 Intravenous

8 Global Acute Repetitive Seizures Market, By Distribution Channel

8.1 Introduction
8.2 Specialty Clinics
8.3 Retail Pharmacies
8.4 Hospitals
8.5 Online Pharmacies

9 Global Acute Repetitive Seizures Market, By End User

9.1 Introduction
9.2 Home Care Settings
9.3 Clinics
9.4 Other End Users

10 Global Acute Repetitive Seizures Market, By Geography

10.1 Introduction
10.2 North America
- 10.2.1 US
- 10.2.2 Canada
- 10.2.3 Mexico
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 Italy
- 10.3.4 France
- 10.3.5 Spain
- 10.3.6 Rest of Europe
10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 New Zealand
- 10.4.6 South Korea
- 10.4.7 Rest of Asia Pacific
10.5 South America
- 10.5.1 Argentina
- 10.5.2 Brazil
- 10.5.3 Chile
- 10.5.4 Rest of South America
10.6 Middle East & Africa
- 10.6.1 Saudi Arabia
- 10.6.2 UAE
- 10.6.3 Qatar
- 10.6.4 South Africa
- 10.6.5 Rest of Middle East & Africa

11 Key Developments

11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies

12 Company Profiling

12.1 Bausch Health Companies Inc.
12.2 UCB Pharma
12.3 Eisai Co., Ltd.
12.4 SK Biopharmaceuticals Co., Ltd.
12.5 Valeant Pharmaceuticals North America LLC
12.6 Sunovion Pharmaceuticals
12.7 GW Pharmaceuticals
12.8 Pfizer Inc.
12.9 Marinus Pharmaceuticals
12.10 Neurelis, Inc.
12.11 Sanofi
12.12 Novartis AG
12.13 Alexza
12.14 Veriton Pharma

急性群発発作の2030年までの市場予測：製品タイプ、投与経路、流通チャネル、エンドユーザー、地域別の世界分析

Acute Repetitive Seizures Market Forecasts to 2030 - Global Analysis By Product (Diastat Rectal Gel, AZ-002, NRL-1, USL-261 and Other Products), Drug Type, Route of Administration, Distribution Channel, End User and By Geography

COVID-19の影響：

最大のシェアを占める地域：

CAGRが最も高い地域：

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

目次

第1章 エグゼクティブサマリー

第2章 序文

第3章 市場動向分析

第4章 ポーターのファイブフォース分析

第5章 世界の急性群発発作市場：製品別

第6章 世界の急性群発発作市場：薬剤タイプ別

第7章 世界の急性群発発作市場：投与経路別

第8章 世界の急性群発発作市場：流通チャネル別

第9章 世界の急性群発発作市場：エンドユーザー別

第10章 世界の急性群発発作市場：地域別

第11章 主な発展

第12章 企業プロファイリング